NEW YORK (GenomeWeb) – Biocept has filed a shelf registration to offer from time to time up to $50 million of its securities.
In a document filed with the US Securities and Exchange Commission on Thursday, the company said that the form of securities to be offered may comprise common stock, preferred stock, debt securities, and warrants.
The San Diego-based firm develops oncology diagnostics based on circulating tumor cell technology. It went public in February 2014 raising $19 million in gross proceeds. This past February, it raised another $15.6 million in net proceeds in a public offering of its securities, according to its Form 10-K.
The firm reported $19.3 million in cash and cash equivalents as of the end of the first quarter.